Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
Seeking Alpha3d
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other ...
inkbotdesign.com2d
Top 20 Fashion Logos: Best Designs in the Industry
Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...
Yahoo Finance3d
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted for ...
Healthline5d
Wakix (Pitolisant) Cost and Financial Assistance
The price you pay for Wakix may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost ...
Healthline6d
Pill Identifier
Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...
Yahoo Finance2d
Axsome Therapeutics, Inc. (AXSM)
After hours: 7:46:26 p.m. EST ...